# Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)

> **NCT00380705** · PHASE4 · COMPLETED · sponsor: **Organon and Co** · enrollment: 91 (estimated)

## Conditions studied

- Asthma
- Rhinitis Allergic

## Interventions

- **DRUG:** MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks

## Key facts

- **NCT ID:** NCT00380705
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-18
- **Primary completion:** 2005-07-29
- **Final completion:** 2005-07-29
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380705, "Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00380705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*